FY2029 Earnings Forecast for ATOS Issued By HC Wainwright

Atossa Therapeutics, Inc. (NASDAQ:ATOSFree Report) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.14) per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share.

Several other research firms also recently commented on ATOS. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th.

Get Our Latest Report on ATOS

Atossa Therapeutics Stock Down 2.7 %

Shares of ATOS opened at $0.84 on Monday. Atossa Therapeutics has a 12 month low of $0.72 and a 12 month high of $2.31. The stock has a market cap of $105.91 million, a price-to-earnings ratio of -3.83 and a beta of 1.26. The company has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $1.26.

Institutional Investors Weigh In On Atossa Therapeutics

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares in the last quarter. Intech Investment Management LLC acquired a new position in Atossa Therapeutics during the third quarter valued at approximately $29,000. The Manufacturers Life Insurance Company acquired a new stake in Atossa Therapeutics during the 3rd quarter worth $75,000. State Street Corp lifted its holdings in shares of Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after purchasing an additional 69,180 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after buying an additional 24,951 shares during the period. 12.74% of the stock is currently owned by institutional investors.

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Further Reading

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.